The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell genetically modified to express a chimeric antigen receptor (CAR) a bispecific antibody or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody a humanized antibody or antigen binding fragments thereof.